Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2648-50. doi: 10.1016/j.bmcl.2014.04.063. Epub 2014 Apr 26.

Abstract

Introducing an aryl moiety to our previous pyrrolidone scaffold by molecule fusing strategy afforded two sets of isopropylether-pyrrolidone and α-phenylethylamine-pyrrolidone derivatives. Two novel compounds 8b and 8g of the latter serial showed potent p53-MDM2 inhibitory activities with Ki values of 90nM which were three-time higher than that of the parent compound. We also confirmed compound 8b can activate p53 proteins in lung cancer A549 cells. The results offered us valuable information for further lead optimization.

Keywords: Arylpyrrolidone; Molecule fusing; Synthesis; p53–MDM2 inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • Drug Design*
  • Humans
  • Imidazolines / chemistry
  • Imidazolines / pharmacology
  • Lung Neoplasms / drug therapy
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-mdm2 / chemistry
  • Proto-Oncogene Proteins c-mdm2 / metabolism*
  • Pyrrolidinones / chemical synthesis
  • Pyrrolidinones / chemistry*
  • Pyrrolidinones / pharmacology*
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*
  • Tumor Suppressor Protein p53 / chemistry
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Antineoplastic Agents
  • Imidazolines
  • Pyrrolidinones
  • RG7112
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2